J. Zhou

发表

A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).

M. Schell, B. El-Rayes, O. Alese, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer

L. Liu, X. Yang, P. Peng, 2020 .

56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial

Yingyong Hou, S. Qiu, Yang Xu, 2020 .

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib

J. Neal, H. Wakelee, C. Liang, 2019, Journal of Thoracic Oncology.

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

B. Han, K. Nan, F. Jin, 2018, Journal of Thoracic Oncology.

Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden

S. Qin, Z. Wang, T. Hou, 2019, Annals of Oncology.

944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial

Q. Ye, Q. Gao, G. Shi, 2021, Annals of Oncology.

Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases.

T. Oliver, G. Browman, L. Thabane, 2004, Journal of Clinical Oncology.

OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

P. Janne, D. Camidge, M. Millward, 2021, Journal of Thoracic Oncology.

LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)

Wanli Yang, Caicun Zhou, Lunxu Liu, 2020 .

1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033

C. Zhou, I. Vynnychenko, V. Sriuranpong, 2020 .

First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis

T. Hsia, F. Branle, P. Yu, 2019, Annals of Oncology.

MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

C. Zhou, Y. Cheng, J. Shao, 2021, Journal of Thoracic Oncology.

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Yunpeng Liu, Dong Wang, Juxian Wang, 2020 .

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC).

Y. Wu, Y. Cheng, H. Pan, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.